



INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/781,442
				Filing Date	February 18, 2004
				First Named Inventor	Chengde Wu, et al
				Group Art Unit	1614-1626 ATP
				Examiner Name	Anthony J. Pavignani
Sheet	1	of	2	Attorney Docket No.	TEX4542P0491US

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	U.S. Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
		Number Kind Code ² (if known)			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Ts
		Country Code ² -Number ³ -Kind Code ⁴ (if known)				
ATP		WO 03/099773 A1	December 4, 2003	Millenium Pharmaceuticals Inc.		
ATP		WO 02/090353 A1	November 14, 2002	Smithkline Beecham Corporation		
ATP		WO 02/089793 A1	November 14, 2002	Smithkline Beecham Corporation		
ATP		WO 02/089740 A2	November 14, 2002	Smithkline Beecham Corporation		
ATP		WO 02/090337 A1	November 14, 2002	Smithkline Beecham Corporation		
ATP		WO 02/089785 A1	November 14, 2002	Smithkline Beecham Corporation		
ATP		WO 02/090348 A1	November 14, 2002	Smithkline Beecham Corporation		
ATP		WO 02/089792 A1	November 14, 2002	Smithkline Beecham Corporation		
ATP		WO 2004/026836 A2	April 1, 2004	Actelion Pharmaceuticals Ltd.		

Examiner: Anthony J. Pavignani

Date Considered: July 8, 2005

Sheet 2 of 2

U.S. Application No. 10/781,442 Inventor: Chengle Wu et al.

Examiner Signature	<i>Anthony J. Bell</i>	Date Considered	<i>July 8, 2005</i>
--------------------	------------------------	-----------------	---------------------

*EXAMINER: Initial if reference considered, ~~whether~~ or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and ~~not~~ considered. Include copy of this form with next communication to applicant. *Applicant's unique citation designation number (optional). * See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. * Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). * For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. * Kind of document by the appropriate symbols as indicated on the document under WIPO Standards ST.16, if possible. * Applicant is to place a checkmark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) and application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

There are no references on this page of the Information Disclosure Statement.
ASP. 7/8/05